+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nonmuscle Invasive Bladder Cancer - Pipeline Insight, 2021

  • ID: 4340489
  • Clinical Trials
  • July 2021
  • Region: Global
  • 80 pages
  • DelveInsight

FEATURED COMPANIES

  • Abraxis Bioscience
  • AstraZeneca
  • Hamlet Pharma
  • Incyte Corporation
  • LIPAC Oncology
  • Rapamycin Holdings
  • MORE
This Nonmuscle invasive bladder cancer - Pipeline Insight, 2021 provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nonmuscle invasive bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Nonmuscle invasive bladder cancer Understanding


Nonmuscle invasive bladder cancer: Overview


Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.

Nonmuscle invasive bladder cancer - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nonmuscle invasive bladder cancer pipeline landscape is provided which includes the disease overview and Nonmuscle invasive bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Nonmuscle invasive bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonmuscle invasive bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Nonmuscle invasive bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Nonmuscle invasive bladder cancer.

Nonmuscle invasive bladder cancer Emerging Drugs Chapters


This segment of the Nonmuscle invasive bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nonmuscle invasive bladder cancer Emerging Drugs


UGN-102: UroGen Pharma

UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Nonmuscle invasive bladder cancer.

Sasanlimab: Pfizer

Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells. PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. Pfizer is developing PF-06801591 for the treatment of Non-muscle Invasive Bladder Cancer and is currently in phase III stage of development.

Nonmuscle invasive bladder cancer: Therapeutic Assessment


This segment of the report provides insights about the different Nonmuscle invasive bladder cancer drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Nonmuscle invasive bladder cancer


There are approx. 30+ key companies which are developing the therapies for Nonmuscle invasive bladder cancer. The companies which have their Nonmuscle invasive bladder cancer drug candidates in the most advanced stage, i.e. Phase III include, UroGen Pharma.

Phases


This report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Nonmuscle invasive bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nonmuscle invasive bladder cancer: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nonmuscle invasive bladder cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonmuscle invasive bladder cancer drugs.

Nonmuscle invasive bladder cancer Report Insights

  • Nonmuscle invasive bladder cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Nonmuscle invasive bladder cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Nonmuscle invasive bladder cancer drugs?
  • How many Nonmuscle invasive bladder cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nonmuscle invasive bladder cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nonmuscle invasive bladder cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Nonmuscle invasive bladder cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • UroGen Pharma
  • CG Oncolgy
  • Sasanlimab
  • Sesen Bio
  • Theralase Technologies
  • Asieris Pharmaceuticals
  • Hamlet Pharma
  • AstraZeneca
  • Viralytics
  • ImmunityBio
  • Prokarium
  • Vaxiion Therapeutics
  • Janssen Pharmaceuticals
  • Abraxis Bioscience
  • LIPAC Oncology
  • Rapamycin Holdings
  • Incyte Corporation
  • Taizhou Hanzhong biomedical

Key Products

  • UGN-102
  • CG 0070
  • Pfizer
  • Vicineum
  • TLD-1433
  • APL-1202
  • Alpha1H
  • Durvalumab
  • CVA 21
  • Inbakicept
  • Vesibax
  • VAX-014
  • Balversa
  • ABI-009
  • TSD-001
  • eRapa
  • Pemigatinib
  • HX008

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abraxis Bioscience
  • AstraZeneca
  • Hamlet Pharma
  • Incyte Corporation
  • LIPAC Oncology
  • Rapamycin Holdings
  • MORE
Introduction

Executive Summary

Nonmuscle invasive bladder cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Nonmuscle invasive bladder cancer - Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis
UGN-102: UroGen Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
TLD 1433: Theralase Technologies
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
VAX-014: Vaxiion Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical/Discovery Stage Products
  • Comparative Analysis
Vesibax: Prokarium
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Nonmuscle invasive bladder cancer Key Companies

Nonmuscle invasive bladder cancer Key Products

Nonmuscle invasive bladder cancer- Unmet Needs

Nonmuscle invasive bladder cancer- Market Drivers and Barriers

Nonmuscle invasive bladder cancer- Future Perspectives and Conclusion

Nonmuscle invasive bladder cancer Analyst Views

Appendix

List of Tables
Table 1 Total Products for Nonmuscle invasive bladder cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Nonmuscle invasive bladder cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • UroGen Pharma
  • CG Oncolgy
  • Sasanlimab
  • Sesen Bio
  • Theralase Technologies
  • Asieris Pharmaceuticals
  • Hamlet Pharma
  • AstraZeneca
  • Viralytics
  • ImmunityBio
  • Prokarium
  • Vaxiion Therapeutics
  • Janssen Pharmaceuticals
  • Abraxis Bioscience
  • LIPAC Oncology
  • Rapamycin Holdings
  • Incyte Corporation
  • Taizhou Hanzhong biomedical
Note: Product cover images may vary from those shown
Adroll
adroll